With the recently reported promising results of the PTP1B-inhibitor Trodusquemine in breast cancer [19], our data provide further rationale for the use of these kinds of PTP1B activity inhibitors as treatment modality for colorectal cancer. This evidence concerns the gene PTPN1 and breast carcinoma.